Eli Lilly will invest over $1.2bn into its manufacturing site in Puerto Rico, as it aims to assemble a robust supply chain ...

Dewpoint Therapeutics has received the US FDA's ODD for DPTX3186, a small-molecule condensate modulator for treating gastric ...

New research confirms Jungbunzlauer’s TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications.

Two of the world’s largest pharmaceutical companies, Pfizer (New York, US) and Roche (Basel, Switzerland), have unveiled more ...

Seres is set to receive up to $3.6m in further non-dilutive funding from the international non-profit partnership, CARB-X.

Elevara’s first-in-class asset ERV001, a CDK4/6 inhibitor, is set to enter Phase II testing as an add-on treatment in RA.

Eli Lilly and NVIDIA will build a new supercomputer to accelerate drug discovery and shorten development cycles.

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...

Leading clinicians, researchers & pharmaceutical innovators gathered to discuss the future of cancer treatment.

MHLW of Japan has granted orphan regenerative medicine product designation to Kyowa Kirin and Orchard Therapeutics’ MLD therapy..